Drug Discovery in Japan Investigating the Sources of Innovation
This book analyzes the drug-discovery process in Japan, based on detailed case studies of 12 groups of 15 innovative drugs. It covers the first statin in the world up to the recent major breakthrough in cancer therapy, the recent immune checkpoint inhibit
- PDF / 6,670,436 Bytes
- 338 Pages / 453.544 x 683.151 pts Page_size
- 36 Downloads / 220 Views
Drug Discovery in Japan Investigating the Sources of Innovation
Drug Discovery in Japan
Sadao Nagaoka Editor
Drug Discovery in Japan Investigating the Sources of Innovation
123
Editor Sadao Nagaoka Department of Economics Tokyo Keizai University Kokubunji, Tokyo, Japan
ISBN 978-981-13-8905-4 ISBN 978-981-13-8906-1 https://doi.org/10.1007/978-981-13-8906-1
(eBook)
© Springer Nature Singapore Pte Ltd. 2019 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd. The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721, Singapore
Preface
This book investigates the sources of drug-discovery innovation in Japan through detailed case studies of the 12 groups of 15 innovative drugs discovered in Japan. Japan is a major contributor to the global drug-discovery industry, as is illustrated by its breakthrough discoveries, such as the first statin and the recent immune checkpoint inhibitor against cancer. This book discusses the knowledge sources of the drug-discovery projects, the interaction between drug discovery and scientific progress, causes of unexpected difficulties, capturing serendipities, and uniqueness and competition in drug discovery, focusing on the sources of innovation. Case studies of the following drugs are covered: compactin/pravastatin (Mevalotin, Pravachol), rosuvastatin (Crestor), leuprorelin (Leuplin, Lupron, Viadur), ofloxacin (Tarivid, Floxin) and levofloxacin (Cravit, Levaquin), tamsulosin (Harnal, Flomax), pranlukast (Onon), tacrolimus (Prograf), pioglitazone (Actos, Glustin), donepezil (Aricept), candesartan (Blopress, Atacand, Amitas), tocilizumab (Actemra), and nivolumab (Opdivo). Many of these drugs offered new treatments to diseases that had been previously intractable and significantly increased the patient le
Data Loading...
